Literature DB >> 12023096

A qualitative study of patient satisfaction with follow-up cancer care: the case of Hong Kong.

Donna Kam Pun Wong1, Sau Fong Chow.   

Abstract

This paper reports the results of a qualitative study that examined the experiences of cancer patients with the intention of incorporating consumer perspectives into the development of quality cancer care in Hong Kong. Altogether, eight focus group interviews were conducted with a total of 41 cancer patients. The results indicate that patients lack clear guidance and support regarding the management of sequelae and surveillance against recurrence. Patients also raised concerns about the lack of access to information, and the lack of health care provider accountability. Any understanding of the scope and goals of follow-up cancer care is obscured when the healthcare environment is not conducive to good doctor-patient communication. Patients are calling for more explicit goals and clinical practice guidelines to serve as frames of reference for both patients and doctors.

Entities:  

Mesh:

Year:  2002        PMID: 12023096     DOI: 10.1016/s0738-3991(01)00168-9

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  3 in total

Review 1.  Patients' and healthcare professionals' views of cancer follow-up: systematic review.

Authors:  Ruth A Lewis; Richard D Neal; Maggie Hendry; Barbara France; Nefyn H Williams; Daphne Russell; Dyfrig A Hughes; Ian Russell; Nicholas S A Stuart; David Weller; Clare Wilkinson
Journal:  Br J Gen Pract       Date:  2009-07       Impact factor: 5.386

2.  Follow-up care in cancer: adjusting for referral targets and extending choice.

Authors:  Kate Wilson; Anne Lydon; Ziv Amir
Journal:  Health Expect       Date:  2011-05-25       Impact factor: 3.377

3.  Care-seeking behavior of Japanese gynecological cancer survivors suffering from adverse effects.

Authors:  Sumiko Oshima; Kengo Kisa; Takayoshi Terashita; Hidenobu Kawabata; Masaji Maezawa
Journal:  BMC Womens Health       Date:  2013-01-08       Impact factor: 2.809

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.